First Impressions from the DOJ/FTC Listening Session on Drug-Price Competition

First Impressions from the DOJ/FTC Listening Session on Drug-Price Competition

Last week’s “listening session” on pharmaceutical competition, hosted jointly by the U.S. Justice Department (DOJ) and Federal Trade Commission (FTC), may go down as an important precursor to the Trump administration’s promised campaign to lower drug prices. While billed as a fact-finding exercise, the discussion revealed competing visions to reform the U.S. pharmaceutical ecosystem, with potentially far-reaching implications for innovation ince…